NCT04882462Unknown2 期
A Multicenter, Single-arm Study of Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The First Affiliated Hospital of Soochow University0 个研究点目标入组 100 人开始时间: 2021年5月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 100
- 主要终点
- Progression Free Survival
研究概览
简要总结
This clinical study is designed as a prospective, open-label, single arm, multicenter study to evaluate the clinical efficacy and safety of Sintilimab and Nimotuzumab in combination with chemotherapy in patients with newly diagnosed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The main endpoint is progression free survival (PFS); the secondary endpoint are objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary and sign a consent form;
- •Age 18-75 years old, gender unlimited;
- •Histology or imaging diagnosed as R/M HNSCC, patients haven't received any anti-tumor treatment for R/M HNSCC; Including oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, paranasal sinus and nasal cavity cancer, etc.;
- •PD-L1 immunohistochemistry and EGFR immunohistochemistry should be performed on tumor tissue samples;
- •according to the efficacy evaluation criteria for solid tumors (RECIST version 1.1), at least one measurable lesion;
- •Not received any previous systemic antitumor therapy for R/M HNSCC. Subjects who had previously received adjuvant/neoadjuvant chemotherapy, or had received radical chemoradiotherapy for advanced disease, were allowed to be enrolled in this study if the interval between disease progression or recurrence and the end of the last treatment (including chemotherapy /EGFR monoclonal antibody /EGFR-TKI/ antiangiogenic agents) was beyond 6 months. Radiotherapy for individual recurrent and/or metastatic lesions cannot be ruled out.
- •ECOG PS 0-2
- •Expected survival time ≥ 3 months;
- •Enough organ function, the participants need to satisfy the following laboratory indicators: 1) nearly 14 days without the use of granulocyte colony stimulating factor, absolute neutrophil count ≥ 1.5 × 109/L; 2) Platelets ≥100×109/L in the case of no blood transfusion in the last 14 days; 3) Hemoglobin ≥9g/dL (90g/L) or≥5.6 mmol/L in the absence of blood transfusion or erythropoietin treatment within the last 14 days; 4) total bilirubin ≤1.5×upper limit of normal (ULN); 5) Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) ≤2.5×ULN, or AST/ALT≤5×ULN in subjects with liver metastasis; 6) Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 mL /min; 7) Good coagulant function; 8) Thyroid function is normal; 9) Myocardial enzyme spectrum is normal;
- •For females of reproductive age, a pregnancy test with negative results should be performed within 3 days prior to receiving the first dosing (cycle 1 day 1);
- •To avoid pregnancy, an effective contraception should used for female patients.
排除标准
- •squamous cell carcinoma of skin;
- •Patients with uncured malignancies other than R/M HNSCC diagnosed within 5 years prior to initial administration;
- •Participating in other clinical studies, or receiving other investigational drugs or using investigational devices within 4 weeks prior to first dosing;
- •Have received any other anti-tumor treatment for R/M HNSCC, including PD-1 inhibitor, PD-L1 inhibitor, CD137 inhibitor, EGFR monoclonal antibody, EGFR-TKI, anti-angiogenic drugs, etc.;
- •Major surgery or chemotherapy was performed within 4 weeks prior to enrollment;
- •Have received immunomodulatory drugs (including thymosin, interferon, interleukin);
- •Active autoimmune disease with systemic therapy (such as glucocorticoids or immunosuppressants) within 2 years prior to initial administration. Alternative therapy (e.g. thyroxine, insulin, etc.) is not considered systemic therapy.
- •Have received systemic glucocorticoid therapy within 7 days prior to enrollment; Note: Physiological dose of glucocorticoids (≤10 mg/ day of prednisone or equivalent drugs) is allowed.
- •Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
- •Allergic to the study drugs;
- •Have not fully recovered from toxicity and/or complications caused by any intervention prior to enrollment;
- •History of human immunodeficiency virus (HIV) infection;
- •Untreated active hepatitis B; Note: Hepatitis B patients who meet the following criteria can also be enrolled: 1) HBV DNA<1000 copies /ml (200 IU/ml) prior to enrollment; 2) anti-HBcAg(+), HBsAg (-), anti-HBsAg (-), and HBV DNA(-), prophylactic anti-HBV therapy is not required, but virus reactivation needs to be closely monitored;
- •Active HCV infection;
- •Live vaccine was given within 30 days;
- •Pregnant or lactating women;
- •Any serious or uncontrollable systemic disease;
- •Other reasons that are not suitable to participate in this study according to the researcher's judgment.
研究组 & 干预措施
single arm
Experimental
干预措施: Nimotuzumab (Drug)
single arm
Experimental
干预措施: Sintilimab (Drug)
single arm
Experimental
干预措施: Chemotherapy drug (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: Up to 12 months
次要结局
- ORR(Up to 12 months)
- OS(Up to 12 months)
- DCR(Up to 12 months)
研究者
相似试验
招募中
2 期
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal CancerMetastatic Esophageal Squamous Cell CarcinomaNCT06138028Qingdao Central Hospital90
Unknown
2 期
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.Hepatocellular CarcinomaNCT03794440Innovent Biologics (Suzhou) Co. Ltd.595
招募中
1 期
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal CancerAnti-PD-1 AntibodyRadiotherapyRectal CancerMSI-HMmr DeficiencyNCT04636008West China Hospital20
招募中
3 期
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06563869The First Affiliated Hospital with Nanjing Medical University40
Unknown
2 期
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLCMetastatic NSCLCRecurrent NSCLCAdvanced Non-Small Cell Squamous Lung CancerNCT04846452The First Affiliated Hospital with Nanjing Medical University40